Bristol Myers pivots from Revlimid drag to Eliquis-fuelled transition year

Feb 5, 2026

Bristol-Myers Squibb Co

Bristol-Myers Squibb Reports Robust Q3 2025, Raises Revenue Outlook

Oct 30, 2025

Bristol-Myers Squibb Co

Bristol-Myers Squibb Delivers Solid Q2 Results with Strong Portfolio Growth

Jul 31, 2025

Bristol-Myers Squibb Co

Bristol-Myers Squibb Q1 2025 Earnings: Growth Portfolio Shines amid Strategic Transition

Apr 24, 2025

Bristol-Myers Squibb Co